Tag - RVV

Developments

Revive oral Bucillamine flunks Phase 3 COVID-19 study

Revive Therapeutics (OTCQB:RVVTF; CSE:RVV) reported that its Phase 3 clinical study evaluating the safety and efficacy of oral Bucillamine in patients with mild- to-moderate COVID-19 did not achieve statistical...

July 6, 2023

Feature

Revive readies key clinical studies in gout and kidney stones

By Len Zehr Revive Therapeutics (TSX-V:RVV; OTCQB:RVVTF) hopes to begin a pivotal Phase 2b clinical trial in mid-year with its Bucillamine drug candidate for the treatment of acute gout flares. “We believe that the...

March 1, 2016

Tag - RVV

Revive oral Bucillamine flunks Phase 3 COVID-19 study

Revive readies key clinical studies in gout and kidney stones

General

More